Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xencor Inc (NASDAQ: XNCR), Atara Biotherapeutics (NASDAQ: ATRA) and DENTSPLY SIRONA Inc (NASDAQ: XRAY) with bullish sentiments.

Xencor Inc (NASDAQ: XNCR)

Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Xencor Inc (NASDAQ: XNCR) today and set a price target of $38. The company’s shares closed yesterday at $30.84.

According to TipRanks.com, Lee is a 4-star analyst with an average return of 4.9% and a 46.4% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.

Currently, the analyst consensus on Xencor Inc is Strong Buy and the average price target is $36.75, representing a 19.2% upside.

In a report issued on April 26, Piper Jaffray also reiterated a Buy rating on the stock with a $46 price target.

See today’s analyst top recommended stocks >>

Atara Biotherapeutics (NASDAQ: ATRA)

Cowen & Co. analyst Eric Schmidt maintained a Buy rating on Atara Biotherapeutics (NASDAQ: ATRA) today. The company’s shares closed yesterday at $42.05.

According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 42.8% and a 60.9% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Alexion Pharmaceuticals, and Akcea Therapeutics Inc.

Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $57.33.

DENTSPLY SIRONA Inc (NASDAQ: XRAY)

In a report released today, Michael Petusky from Barrington maintained a Buy rating on DENTSPLY SIRONA Inc (NASDAQ: XRAY), with a price target of $54. The company’s shares closed yesterday at $46.92, close to its 52-week low of $46.

Petusky observed:

“We are maintaining our OUTPERFORM investment rating, but significantly reducing our price target to $54 (from $70) given our reduced profitability estimates and a lowering of our multiple to 15x (from 18x). We arrive at our price target by attaching an 15x multiple to our 2018 adjusted EBITDA estimate. We assume $1.3 billion in net debt 12 months from now.”

According to TipRanks.com, Petusky is a 4-star analyst with an average return of 12.1% and a 60.5% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.

Currently, the analyst consensus on DENTSPLY SIRONA Inc is Moderate Buy and the average price target is $60.71, representing a 29.4% upside.

In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $57 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.